Increased expressions of SRPK1 and SRPK2 are linked to progressive signatures of carcinogenesis, such as active proliferation and anti-apoptosis, in cancer cells [39,40], whereas altered expressions of SRPK1 and SRPK2 were demonstrated to exhibit both oncogenic and tumor-suppressive effects in in vitro cell and animal models [41]. The gene discussed is SRPK2; the disease is cancer.